Roche
NEWS
Please check out the biopharma industry’s COVID-19 stories that are trending for April 20, 2021.
As biopharma companies focus on efficiencies and close sites, jobs are getting lost. Here’s a look.
There was a fair amount of clinical trial news last week. Here’s a look.
Ionis Pharmaceuticals announced that its collaboration partner, Roche, was discontinuing dosing in the Phase III GENERATION HD1 trial of tominersen in manifest Huntington’s disease (HD).
Roche’s checkpoint inhibitor Tecentriq (atezolizumab) hit the mark in the company’s Phase III IMpower010 trial of the drug compared to best supportive care in people with resectable early-stage lung cancer.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 16, 2021.
Shares of GenMark Diagnostics are soaring in premarket trading after Roche announced it was acquiring the California-based company in a $1.8 billion deal to bolster its own diagnostics pipeline.
It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson’s disease, Alzheimer’s, HIV and more.
Roche announced it was voluntarily withdrawing the U.S. indication Tecentriq for in prior-platinum treated metastatic urothelial carcinoma (mUC) after failing to meet endpoints in confirmatory trials.
JOBS
IN THE PRESS